An observational study in Cerebral Small Vessel Diseases, Lacunar Stroke and Vascular Dementia, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by University of Edinburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are:
Participants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels.
Participants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.
Cerebral small vessel disease (SVD) is a common cause of stroke and dementia. The molecular causes are unclear, limiting new therapies. Breakdown of the blood-brain barrier (BBB) is characteristic and may damage brain tissue. However, specialist MRI scans to measure BBB breakdown are expensive and time-consuming.
In contrast, measuring leakage from retinal blood vessels is relatively simple. The blood-retina barrier is very similar to the BBB, and SVD is likely to damage retinal and brain blood vessels in the same way. If so, then retinal angiography could be used to study SVD pathogenesis and measure the effect of new treatments with much greater resolution and lower cost than MRI.
We have three aims:
We will recruit participants from a well-established cohort of people with SVD - the Mild Stroke Study 3 (MSS3).
21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.
Browse Stroke, Lacunar studies →University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
Compared within Stroke, Lacunar, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cerebral Small Vessel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adults >18 years old with mild ischaemic stroke with a modified Rankin scale (mRS) greater or equal to 2 at recruitment presenting to Edinburgh/Lothian stroke services.
For details see Clancy, et al (2021) Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. European Stroke Journal 6:81-88. https://doi.org/10.1177/2396987320929617
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
Retinal vessel leakage by automated segmentation
The presence and severity of retinal vessel leakage will be measured for each eye in terms of change in pixel brightness over the duration of the angiogram.
Time frame: within one angiogram
Retinal vessel leakage by manual grading
The presence and severity of retinal vessel leakage will be measured using an manual ordinal grading scale
Time frame: within one angiogram
Baseline blood-brain barrier breakdown
BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium
Time frame: Within one MRI scan
White matter hyperintensity (WMH) volume adjusted for brain volume
This is measured from the most recent structural MRI scan
Time frame: Within one MRI scan
Change in white matter hyperintensity (WMH) volume adjusted for brain volume
This is measured by comparing the most recent structural MRI scan with the baseline structural MRI scan
Time frame: Difference in MRI scans up to 5 years prior
Fazekas score
This is measured from the most recent structural MRI scan
Time frame: Within one MRI scan
Change in Fazekas score
This is measured by comparing the most recent structural MRI scan with the baseline structural MRI scan
Time frame: Difference in MRI scans up to 5 years prior
Baseline average leakage in white matter hyperintensities
BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium
Time frame: Within one MRI scan
Baseline average leakage in deep grey matter
BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium
Time frame: Within one MRI scan
Baseline number of leakage hotspots
BBB breakdown is measured by MRI in terms of image enhancement after intravenous gadolinium
Time frame: Within one MRI scan
Plan to share: Undecided
Started Jan 2025 (actual). Primary completion is estimated for Feb 2029, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.